Overview of rare movement disorders

CONTINUUM Lifelong Learning in Neurology

Volumn 16, Issue 1, 2010, Pages 49-76

  Poston, Kathleen Lombard ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; ANABOLIC AGENT; ANTICONVULSIVE AGENT; ANTIEMETIC AGENT; ANTIHISTAMINIC AGENT; ANTIPARKINSON AGENT; BENZODIAZEPINE; BOTULINUM TOXIN; CARBAMAZEPINE; CIMETIDINE; COCAINE; DIGOXIN; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; FLUNARIZINE; ISONIAZID; LEVODOPA; LITHIUM; METHADONE; METHYLDOPA; METOCLOPRAMIDE; NEUROLEPTIC AGENT; ORAL CONTRACEPTIVE AGENT; PHENYTOIN; RESERPINE; STEROID; TETRABENAZINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROIC ACID;

ALZHEIMER DISEASE; ARTICLE; AUTONOMIC DYSFUNCTION; BLEPHAROSPASM; BRADYKINESIA; BRAIN METABOLISM; CHOREA; CLINICAL FEATURE; CORTICOBASAL DEGENERATION; DEMENTIA; DENTATORUBROPALLIDOLUYSIAN ATROPHY; DEPRESSION; DIFFERENTIAL DIAGNOSIS; DIFFUSION WEIGHTED IMAGING; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG DOSE INCREASE; DRUG INDUCED DISEASE; DYSARTHRIA; DYSKINESIA; DYSPHAGIA; ECHOGRAPHY; ELECTROMYOGRAPHY; FALLING; FOCAL DYSTONIA; FRONTOTEMPORAL DEMENTIA; GAIT DISORDER; HUMAN; HUNTINGTON CHOREA; HYPERSALIVATION; INTERMITTENT CATHETERIZATION; LEWY BODY; LOW DRUG DOSE; MOTOR DYSFUNCTION; MUSCLE RIGIDITY; MYOCLONUS; NEUROIMAGING; NEUROLOGIC DISEASE; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; OROFACIAL DYSKINESIA; ORTHOSTATIC HYPOTENSION; PALLIATIVE THERAPY; PARKINSON DISEASE; PARKINSONISM; PHYSIOTHERAPY; POSITRON EMISSION TOMOGRAPHY; PROGRESSIVE SUPRANUCLEAR PALSY; SCINTIGRAPHY; SHY DRAGER SYNDROME; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SOCIAL SUPPORT; SPEECH THERAPY; TAUOPATHY; TRANSCRANIAL SONOGRAPHY; TREATMENT INDICATION; TREATMENT RESPONSE; URINE INCONTINENCE;

EID: 78650718588     PISSN: 10802371     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.CON.0000348900.09963.bc     Document Type: Article

References (45)

1. Bensimon G, Ludolph A, Agid Y, et al. Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: The NNIPPS study. Brain 2009;132(pt 1):156-171.
2. Berry-Kravis E, Abrams L, Coffey SM, et al. Fragile X-associated tremor/ataxia syndrome: Clinical features, genetics, and testing guidelines. Mov Disord 2007;22(14): 2018-2030.
3. Boeve BF, Lang AE, Litvan I. Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. Ann Neurol 2003;54(suppl 5):S15-S19.
4. Boxer AL, Geschwind MD, Belfor N, et al. Patterns of brain atrophy that differentiate corticobasal degeneration syndrome from progressive supranuclear palsy. Arch Neurol 2006;63(1):81-86.
5. Brooks DJ, Seppi K; Neuroimaging Working Group on MSA. Proposed neuroimaging criteria for the diagnosis of multiple system atrophy. Mov Disord 2009;24(7):949-964.
6. Dickson DW, Rademakers R, Hutton ML. Progressive supranuclear palsy: pathology and genetics. Brain Pathol 2007;17(1):74-82.
7. Eckert T, Barnes A, Dhawan V, et al. FDG PET in the differential diagnosis of parkinsonian disorders. Neuroimage 2005;26(3):912-921.
8. Feigin A, Tang C, Ma Y, et al. Thalamic metabolism and symptom onset in preclinical Huntington's disease. Brain 2007;130(pt 11):2858-2867.
9. Galpern WR, Lang AE. Interface between tauopathies and synucleinopathies: A tale of two proteins. Ann Neurol 2006:59(3):449-458.
10. Geda YE, Boeve BF,NegashS, et al. Neuropsychiatric features in 36 pathologically confirmed cases of corticobasal degeneration. J Neuropsychiatry Clin Neurosci 2007;19(1):77-80.
11. Gilman S, Wenning GK, Low PA, et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008;71(9):670-676.
12. Graber JJ, Staudinger R. Teaching neuroimages: "penguin" or "hummingbird" sign and midbrain atrophy in progressive supranuclear palsy. Neurology 2009;72(17):e81.
13. Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002;125(pt 4):861-870.
14. Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: A randomized controlled trial. Neurology 2006;66(3):366-372.
15. Iranzo A. Sleep and breathing in multiple system atrophy. Curr Treat Options Neurol 2007;9(5):347-353.
16. Jankovic J, Orman J. Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias. Neurology 1988;38(3):391-394.
17. Kaplan B, Ratner V, Haas E. Alpha-synuclein-its biological function and role in neurodegenerative diseases. J Mol Neurosci 2003;20(2):83-92.
18. Köllensperger M, Geser F, Seppi K, et al. Red flags for multiple system atrophy. Mov Disord 2008;23(8):1093-1099.
19. Kompoliti K, Goetz CG, Boeve BF, et al. Clinical presentation and pharmacological therapy in corticobasal degeneration. Arch Neurol 1998;55(7):957-961.
20. Lee WH, Lee CC, Shyu WC, et al. Hyperintense putaminal rim sign is not a hallmark of multiple system atrophy at 3T. AJNR Am J Neuroradiol 2005;26(9):2238-2242.
21. Ludolph AC, Kassubek J, Landwehrmeyer BG, et al. Tauopathies with parkinsonism: Clinical spectrum, neuropathologic basis, biological markers, and treatment options. Eur J Neurol 2009;16(3):297-309.
22. Mahapatra RK, Edwards MJ, Schott JM, Bhatia KP. Corticobasal degeneration. Lancet Neurol 2004;3(12):736-743.
23. Nicoletti G, Lodi R, Condino F, et al. Apparent diffusion coefficient measurements of the middle cerebellar peduncle differentiate the Parkinson variant of MSA from Parkinson's disease and progressive supranuclear palsy. Brain 2006;129(pt 10):2679-2687.
24. Noguchi M, Yoshita M, Matsumoto Y, et al. Decreased beta-amyloid peptide42 in cerebrospinal fluid of patients with progressive supranuclear palsy and corticobasal degeneration. J Neurol Sci 2005;237(1-2):61-65.
25. O'sullivan SS, Massey LA, Williams DR, et al. Clinical outcomes of progressive supranuclear palsy and multiple system atrophy. Brain 2008;131(pt 5):1362-1372.
26. Papp MI, Kahn JE, Lantos PL. Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome). J Neurol Sci 1989;94(1-3):79-100.
27. Paulsen JS, Hoth KF, Nehl C, Stierman L. Critical periods of suicide risk in Huntington's disease. Am J Psychiatry 2005;162(4):725-731.
28. Phillips W, Shannon KM, Barker RA. The current clinical management of Huntington's disease. Mov Disord 2008;23(11):1491-1504.
29. Poston KL, Eidelberg D. Network biomarkers for the diagnosis and treatment of movement disorders. Neurobiol Dis 2009;35(2):141-147.
30. Quattrone A, Nicoletti G, Messina D, et al. MR imaging index for differentiation of progressive supranuclear palsy from Parkinson disease and the Parkinson variant of multiple system atrophy. Radiology 2008;246(1):214-221.
31. Shih LC, Tarsy D. Deep brain stimulation for the treatment of atypical parkinsonism. Mov Disord 2007;22(15):2149-2155.
32. Shiryaev N, Jouroukhin Y, Giladi E, et al. NAP protects memory, increases soluble tau and reduces tau hyperphosphorylation in a tauopathy model. Neurobiol Dis 2009;34(2):381-388.
33. Spetsieris PG, Ma Y, Dhawan V, Eidelberg D. Differential diagnosis of parkinsonian syndromes using PCA-based functional imaging features. Neuroimage 2009;45(4): 1241-1252.
34. Stefani A, Lozano AM, Peppe A, et al. Bilateral deep brain stimulation of the pedunculopontine and subthalamic nuclei in severe Parkinson's disease. Brain 2007;130(pt 6):1596-1607.
35. Tada M, Onodera O, Ozawa T, et al. Early development of autonomic dysfunction may predict poor prognosis in patients with multiple system atrophy. Arch Neurol 2007;64(2):256-260.
36. Vandenberghe W, Demaerel P, Dom R, Maes F. Diffusion-weighted versus volumetric imaging of the striatum in early symptomatic Huntington disease. J Neurol 2009;256(1):109-114.
37. Vlaar AM, de Nijs T, van Kroonenburgh MJ, et al. The predictive value of transcranial duplex sonography for the clinical diagnosis in undiagnosed parkinsonian syndromes: Comparison with SPECT scans. BMC Neurol 2008;8:42.
38. Wardle M, Morris HR, Robertson NP. Clinical and genetic characteristics of non-Asian dentatorubral-pallidoluysian atrophy: A systematic review. Mov Disord 2009;24(11):1636-1640.
39. Wenning GK, Litvan I, Jankovic J, et al. Natural history and survival of 14 patients with corticobasal degeneration confirmed at postmortem examination. J Neurol Neurosurg Psychiatry 1998;64(2):184-189.
40. Wenning GK, Stefanova N. Recent developments in multiple system atrophy. J Neurol 2009;256(11):1791-1808.
41. Wenning GK, Stefanova N, Jellinger KA, et al. multiple system atrophy: A primary oligodendrogliopathy. Ann Neurol 2008;64(3):239-246.
42. Williams DR, de Silva R, Paviour DC, et al. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism. Brain 2005;128(pt 6):1247-1258.
43. Williams DR, Lees AJ. Progressive supranuclear palsy: Clinicopathological concepts and diagnostic challenges. Lancet Neurol 2009;8(3):270-279.
44. Yamada M, Shimohata M, Sato T, et al. Polyglutamine disease: Recent advances in the neuropathology of dentatorubral-pallidoluysian atrophy. Neuropathology 2006;26(4):346-351.
45. Zadikoff C, Fox SH, Tang-Wai DF, et al. A comparison of the mini mental state exam to the Montreal cognitive assessment in identifying cognitive deficits in Parkinson's disease. Mov Disord 2008;23(2):297-299.